Scott R Berry
Overview
Explore the profile of Scott R Berry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samuel J, Booth C, Eisenhauer E, Brundage M, Berry S, Gyawali B
JAMA Oncol
. 2022 Apr;
8(6):879-886.
PMID: 35482347
Importance: Although quality of life (QOL) is an important clinical end point, cancer drugs are often approved based on overall survival (OS) or putative surrogate end points such as progression-free...
2.
3.
Srivastava A, Jalink M, Moraes F, Booth C, Berry S, Rubagumya F, et al.
JCO Glob Oncol
. 2021 Jun;
7:925-933.
PMID: 34138643
Existing literature has described the projected increase in cancer incidence and the associated deficiencies in the cancer workforce. However, there is currently a lack of research into the necessary policy...
4.
Chen E, Jonker D, Loree J, Kennecke H, Berry S, Couture F, et al.
JAMA Oncol
. 2020 May;
6(6):831-838.
PMID: 32379280
Importance: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective: To evaluate whether combining...
5.
Chan K, Guo H, Cheng S, Beca J, Redmond-Misner R, Isaranuwatchai W, et al.
Cancer Med
. 2019 Nov;
9(1):160-169.
PMID: 31724340
Background: In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) have been publicly funded for first-line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015....
6.
Trinh L, Arbour-Nicitopoulos K, Sabiston C, Berry S, Loblaw A, Alibhai S, et al.
Int J Behav Nutr Phys Act
. 2018 Dec;
15(1):124.
PMID: 30514302
Following publication of the original article [1], the author has requested us to make a correction in the Results section of the Abstract and in the Discussion sections as explained...
7.
Trinh L, Arbour-Nicitopoulos K, Sabiston C, Berry S, Loblaw A, Alibhai S, et al.
Int J Behav Nutr Phys Act
. 2018 Jun;
15(1):49.
PMID: 29880049
Background: Given the high levels of sedentary time and treatment-related side effects in prostate cancer survivors (PCS), interventions targeting sedentary behavior (SED) may be more sustainable compared to physical activity...
8.
Karim S, Brennan K, Nanji S, Berry S, Booth C
JAMA Oncol
. 2017 Jun;
3(10):1386-1392.
PMID: 28594974
Importance: Recent data have suggested that disease biology and outcome of colon cancer may differ between right-sided and left-sided tumors. However, the literature on the prognostic value of tumor laterality...
9.
Jamani R, Lee E, Berry S, Saluja R, DeAngelis C, Giotis A, et al.
Eur J Clin Pharmacol
. 2016 Aug;
72(11):1391-1399.
PMID: 27561266
Purpose: Abiraterone acetate (AA), used to treat metastatic castration-resistant prostate cancer (mCRPC), inhibits androgen biosynthesis by blocking cytochrome P450 (CYP) 17A1. It also inhibits other cytochromes involved in the metabolism...
10.
Riesco-Martinez M, Berry S, Ko Y, Mittmann N, Giotis A, Lien K, et al.
J Oncol Pract
. 2016 May;
12(6):e710-23.
PMID: 27143148
Purpose: Patients with unresectable wild-type KRAS metastatic colorectal cancer benefit from fluoropyrimidines (FP), oxaliplatin (O), irinotecan (I), bevacizumab (Bev), and epithelial growth factor receptor inhibitors (EGFRI). The most cost-effective regimen...